Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Editas Medicine (EDIT) FCF Margin: 2015-2025

Historic FCF Margin for Editas Medicine (EDIT) over the last 10 years, with Sep 2025 value amounting to -414.64%.

  • Editas Medicine's FCF Margin rose 9058372.00% to -414.64% in Q3 2025 from the same period last year, while for Sep 2025 it was -389.59%, marking a year-over-year decrease of 7974.00%. This contributed to the annual value of -678.07% for FY2024, which is 50283.00% down from last year.
  • According to the latest figures from Q3 2025, Editas Medicine's FCF Margin is -414.64%, which was up 70.45% from -1,403.35% recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's FCF Margin registered a high of -39.21% during Q4 2023, and its lowest value of -115,757.14% during Q3 2022.
  • For the 3-year period, Editas Medicine's FCF Margin averaged around -10,259.34%, with its median value being -1,028.62% (2025).
  • Its FCF Margin has fluctuated over the past 5 years, first plummeted by 11,506,118bps in 2022, then surged by 11,508,814bps in 2023.
  • Quarterly analysis of 5 years shows Editas Medicine's FCF Margin stood at -300.16% in 2021, then plummeted by 35,616bps to -656.32% in 2022, then spiked by 61,711bps to -39.21% in 2023, then plummeted by 12,842bps to -167.63% in 2024, then skyrocketed by 9,058,372bps to -414.64% in 2025.
  • Its FCF Margin was -414.64% in Q3 2025, compared to -1,403.35% in Q2 2025 and -1,028.62% in Q1 2025.